Biostock inverview with acting CEO: ”We aim to drive innovation that accelerates breakthroughs in regenerative medicine”

April 1, 2025
Language flag

With the introduction of the HoloMonitor CellSync, Phase Holographic Imaging (PHI) leaps forward in live cell imaging technology. Currently in the final stages of development, this next-generation imaging system is undergoing pre-production testing at prestigious U.S. institutions – the Huntsman Cancer Institute and the Wake Forest Institute of Regenerative Medicine. Biostock has interviewed the acting CEO, Ivan Jurković, to learn more.

In the interview, Ivan discusses his dual roles at PHI and Altium, explaining how this strategic alignment strengthens both companies. He highlights the advancements of the new HoloMonitor CellSync, particularly its improved imaging capabilities and role in accelerating research in regenerative medicine. Additionally, he outlines PHI’s plans for market expansion, emphasizing the importance of innovation, strategic partnerships, and global outreach to drive adoption and long-term growth.

This year will be record-breaking and the most successful chapter in our company’s history. With a new instrument on the horizon and the opportunities we see, we anticipate steady growth and another strong year to celebrate

Ivan Jurković
CEO
Read the full interview at Biostock

Latest News

A journal cover from Advanced Biology with yellow and blue melanocytes and melanoma cells.

Picture-Perfect Science! HoloMonitor® Images Featured on Cover of Advanced Biology

We are proud to announce that a recent study utilizing HoloMonitor® M4 has been featured on the cover of Advanced Biology, Volume 9, Issue 2 (February 2025). The study, led by Dr. Besa Xhabija and colleagues at the University of Michigan-Dearborn, USA, demonstrates the transformative potential of HoloMonitor, our non-invasive, real-time live cell imaging system, in advancing melanoma research.
A pen and a calculator placed on top of papers with charts.

Interim Report 3 2024/25

Sales grew significantly for both Q3 and YTD, outperforming the FY results of the previous year. Gross margin continues to be strong, even slightly above planned levels (+4pp). Overall costs remain stable and as per plan, with higher administrative costs due to the capital raise offset by lower R&D expenses. The absolute key to transforming the Company, both short-term and long-term, is a significant increase in sales, which is expected due to a strong pipeline and company potential.

Phase Holographic Imaging Announces Next Generation HoloMonitor

Phase Holographic Imaging (PHI) is pleased to announce that the next generation of PHI’s live cell imaging system enters its final development stage. The new model is currently undergoing pre-production testing both internally and externally at the Huntsman Cancer Institute and Wake Forest Institute of Regenerative Medicine.
See All News